forecast
Moving from GBM to larger markets multiplies addressable patients
The company's growth opportunity is to penetrate the remaining 60 percent of eligible US GBM patients and then expand to much larger cancers, such as roughly 200,000 new lung cases and 40,000 pancreatic cases, plus breast and international markets.
forecastpending
Speaker
BillEvidence Quote
“So non-small cell lung cancer, 200,000. Pancreatic, 40,000”
Created: 11/19/2026, 2:27:17 AM
Your notes
Loading notes...